CWC. Michael White

C. Michael White

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


C. Michael White has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Manufacturing Quality Issues in Healthcare and Cosmetics: An Analysis of FDA Surveillance Data

    by Ethan M. Coleman, C. Michael White

    Background: Poor manufacturing quality in healthcare and cosmetic products expose people to danger and needs further categorization and assessment. Objective: This study reviewed Food and Drug Administration (FDA) records to identify major types of quality issues, the type of products involved, and patterns occurring over time. Methods: The “FDA Health Fraud Product” and “FDA Recalls, Market Withdrawals, and Safety Alerts” databases were assessed from June 4, 2010, through May 30, 2026. Drugs, cosmetics, and dietary supplements/quasi-legal products with verified manufacturing quality issues were included. Products were sorted by product type and FDA warning letters or official reports were reviewed and categorized. Results: Of 266 reviewed entries, 195 manufacturing quality issues were elucidated from 184 unique products. Drugs accounted for 70% of issues, cosmetics for 21%, and dietary supplement/quasi-legal products for 9%, respectively. Overall, chemical contamination (30%), procedural or testing issues (29%), and microbial contamination (19%) comprised 78% of identified issues. Drug issues were primarily procedural/testing, chemical contamination, and microbial contamination; cosmetic issues were predominantly elemental impurities and chemical contamination; and dietary supplement/quasi-legal issues were mainly microbial contamination, procedural/testing, and elemental impurities. Particulate contamination occurred only in drugs. The number of issues per year showed no consistent trend, but spiked in 2020, 2022, 2024, and 2025. Conclusion and Relevance: Manufacturing quality problems varied substantially by product category and occurred in irregular clusters. Inconsistent FDA reporting practices and fluctuations in agency surveillance may have contributed to these patterns. Budgetary cuts to the FDA could increase consumer exposure to manufacturing issues.

  • Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription

    by Ava Sedensky, Klaus Nuzi, Laura Nolan, Jordyn Belcourt, C. Michael White

    A legal loophole allows consumers to purchase peptide semaglutide without a prescription, but websites that sell them do not sell supplies or provide guidance. We assessed the ability and confidence of college students at the University of Connecticut and older adults in performing the required steps from September 1, 2025, through January 30, 2026. Participants looked up information online. We provided various semaglutide and diluent vials and supplies. We assessed 34 steps in the process and assigned 1 point for each step successfully completed. We rated confidence on a scale from 1 (no confidence) to 5 (complete confidence). We evaluated 20 adults aged ≥18 years (12 male, 8 female) with a mean (SD) age of 40 (21) years. Participants completed 15 of the 34 steps correctly (mean [SD] = 44% [50%]). We found errors that could result in incorrect dosing, needle sticks, or infections. Mean (SD) confidence was low before and after the demonstration but not significantly so (2.3 [0.7] vs 1.9 [1.0]; P = .19). Untrained adults without experience injecting medications could be at high risk of adverse events when they try to self-administer grey market peptide semaglutide products using only internet information. Future studies should assess a larger and more diverse population and determine whether the results are similar with other products sold as peptides without a prescription.


  • Identification and Characterization of Mitragynine or 7-Hydroxymitraynine Oral Dosage Form Products That Appeal to Children

    by C. Michael White, Mia Atallah, Dana El Khoury

    OBJECTIVE: Kratom is the pulverized dried leaves of the Mitragyna speciosa tree and has a bitter taste and high ingestion volume that repels children. Newer products use a single alkaloid extract from the leaves, mitragynine, or oxidize mitragynine to 7-hydroxymitragynine and place it in various oral dosage forms. We identified oral dosage form products containing mitragynine and/or 7-hydroxymitragynine that are marketed in ways that appeal to children and define their alluring characteristics. METHODS: We performed Google searches to identify websites selling kratom products. Products were assessed and included if they had 1 or more features that would be attractive to children and defined their formulations, alkaloids, flavoring/scents, mascots, and packaging. RESULTS: Eighty unique products that appealed to children were found, and 36.3% were gummies, 28.8% were tablets, 18.8% were drink mixes or liquids, 15.0% were miscellaneous candies (saltwater taffies, ice cream cones, noobs, popping crystals, honey sticks, mints, lollipops), and 1.3% were chocolates. Thirty-eight products (47.5%) contained mitragynine, 35 products (43.8%) contained 7-hydroxymitragynine, 6 products (7.5%) contained both, and 1 product (1.3%) did not specify which alkaloid was included. Twenty-six products (32.5%) had a cartoon mascot or symbol. Sixty-six products (82.5%) had brightly colored packaging, 59 products (73.8%) had brightly colored formulations, and 73 formulations (91.3%) had a flavor or scent. CONCLUSIONS: Mitragynine and 7-hydroxymitragynine are present in many products that could cause small children and teens to be exposed.


  • Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown

    by Jordyn Belcourt, Amy Sapowadia, C. Michael White

    Background: With the shortage of innovator semaglutide or tirzepatide products resolved, compounding pharmacies can only legally sell unique products. Unique products could have a different route of administration or dosing, or could include additional pharmaceutical ingredients. Objective: To identify and characterize compounded semaglutide and tirzepatide products that differ from available FDA-approved products. Methods: We searched compounding sites between February 3, 2025, and March 20, 2025, using key terms [“compounded semaglutide,” “compounded tirzepatide,” and “compounded GLP-1s”] on Google looking for products with a strength, route of administration, and/or formulation that differed from commercially available products. Results: We identified 33 unique semaglutide and/or tirzepatide products. Two-thirds contained semaglutide, and one-third contained tirzepatide. Forty-eight percent of products contained either semaglutide or tirzepatide with some combination of cyanocobalamin, glycine, niacinamide, docusate, or ondansetron. The 17 single active ingredient products were provided in sublingual (82%) or oral disintegrating tablet (ODT) (18%) formulations. Only 18% of included compounded products reported information about beyond use date and preferred storage conditions. Twenty-eight percent reported preferred storage conditions. Conclusion and Relevance: We found little justification for adding nutrients or docusate sodium to combination subcutaneous semaglutide or tirzepatide products. There is a rationale for adding ondansetron, but evidence for subcutaneous administration is lacking. There is a rationale for fashioning sublingual or ODT formulations, but whether these formulations offer advantages over innovator oral tablets has not been determined. The popularity of these products as an alternative to FDA-approved medications is concerning, given the lack of evidence for safety and efficacy.


  • Nonswallowed Kratom-Derived Products: Unlawful Dietary Supplements That Endanger Public Health

    by C. Michael White, Ava Sedensky, Jordyn Belcourt, Pranjali Kulkarni

    The Dietary Supplement Health and Education Act of 1994 specified that dietary supplements must be swallowed. In this study, we investigated whether kratom-derived products are being sold to consumers in nonswallowed formulations. Kratom is the fresh or dried leaf powder of the Mitragyna speciosa tree. We identified 49 kratom-derived products being sold in the form of sublingual strips (24%), buccal pouches (8%), and vaping products (67%). Most contained 7-hydroxymitragynine (an alkaloid that the US Food and Drug Administration seeks to make a controlled substance), but we also identified mitragynine extract and mitragynine pseudoindoxyl products. The majority had flavoring or a scent, and some had mascots, pictures of fruit or mint, or formulation colors or packaging that could appeal to children. Most products were not sold in child-resistant packaging. Several kratom vaping products additionally contained intoxicating hemp cannabinoids. With no clinical, safety, or pharmacokinetic data for kratom-derived products that bypass first-pass metabolism (ie, where a chemical absorbed through the stomach or intestines is metabolized in the liver before reaching the general bloodstream), people should be advised to avoid these products, and regulatory action is needed to prevent their sale to consumers.


  • Transdermal “Natural GLP-1” Dietary Supplements Violate Law and Place Patients at Risk

    by C. Michael White, Zeeya Tai, Klaus Nuzi

    Consumers precluded from obtaining semaglutide or tirzepatide by clinicians or insurers are turning to natural “GLP-1” transdermal patches. The Dietary Supplement Health and Education Act specifies dietary supplement products must be swallowed, so all these products are illegal. We identified 24 transdermal patch dietary supplement products and 1 transdermal gel product with an average of 7 ± 4 natural ingredients (berberine, glutamine/glutamate, cinnamon, and pomegranate most listed). No certificates of analysis were posted, many products lacked the Food and Drug Administration disclaimer, and many products used deceptive advertising. Several products had 1- to 2-star reviews and consumer comments suggesting lack of efficacy or adverse events.

  • A Descriptive Assessment of Products Containing the Opioid Receptor Stimulator Mitragynine Pseudoindoxyl

    by C. Michael White, Jordyn Belcourt, Ava Sedensky

    Background: Potent semi-synthetic alkaloids that stimulate opioid receptors are being sold to consumers in gas stations, smoke shops, and online as the dietary supplement 'kratom'. Objective: We descriptively evaluated the characteristics of products containing mitragynine pseudoindoxyl. Results: Fifty-one unique products met our inclusion criteria. Seventy-one percent of products contained mitragynine pseudoindoxyl plus 7-hydroxymitragynine, 24% contained mitragynine pseudoindoxyl alone (24%), and 6% contained mitragynine pseudoindoxyl with 8-hydroxymitragynine or 11-hydroxymitragynine (with or without 7-hydroxymitragynine). Sixty-nine percent of products had a child appealing flavoring and/or scent, 63% of products were formulated using bright colors or had bright colors on their labeling, 12% of products had food pictures on the label (mainly representing the fruit or mint flavoring/scent), 6% of products had a cartoon mascot, and 6% of products had a food formulation (ice cream cone or chocolate bar). Only 18% of websites disclosed the products stimulated opioid receptors while 45% disclosed they could cause intoxication, tolerance, dependence, withdrawal, or addiction. Conclusions: There are many products that contain mitragynine pseudoindoxyl sold as dietary supplements and many have features that would appeal to children.


  • Believing FDA’s Assurance of Quality Pharmaceutical Products Can Be Dangerous to Your Patients’ Health

    by C. Michael White, Lyla R. White

    The Food and Drug Administration (FDA) exists to protect US consumers. However, while drug manufacturing has shifted dramatically to developing countries like India and China, the FDA first silently followed a “trust and not verify” strategy with virtually no overseas inspections until overwhelming evidence of patient harm had occurred. The implementation of the Generic Drug User Fee Act helped alleviate this problem, but the issue recurred after the COVID-19 pandemic set the FDA far behind in foreign inspections. Regardless, the FDA has never attained parity in inspection frequency and rigor in these countries versus the United States. The FDA still over relies on reports of adverse events, whistleblower reports, and independent laboratory findings to prompt an investigation. When serious issues are found in a manufacturing plant, they redact the products manufactured there so clinicians and patients are unprotected. This has directly harmed US citizens, exposed them to cancer-causing agents, and provided products without the expected benefits. When rates of adverse events were recently compared by manufacturer location, they were found to be markedly higher for manufacturers in emerging countries than advanced countries, especially when a drug’s patent has been expired for a longer time. Clinicians may be dismissive of patients claiming that a new version of a generic drug isn’t as effective as their previous one or is causing new adverse events, but that could be the case. Healthcare professionals should report these cases to the FDA to raise awareness of potential issues.